Table 1 Characteristics of 85 NSCLC patients with EGFR mutations who received ICIs at baseline
Items | Number (%) |
|---|---|
Total | 85 (100%) |
Age | |
  ≤ 60 | 48 (56.5%) |
  > 60 | 37 (43.5%) |
Sex | |
 Male | 45 (52.9%) |
 Female | 40 (47.1%) |
Smoking History | |
 Yes | 35 (41.2%) |
 No | 50 (58.8%) |
PS | |
 0–1 | 61 (71.8%) |
 2 | 24 (28.2%) |
Stage | |
 IV | 85 (100%) |
Histologic type | |
 Squamous carcinoma | 2 (2.4%) |
 Adenocarcinoma | 83 (97.6%) |
Lines | |
 2 | 30 (35.3%) |
  ≥ 3 | 55 (64.7%) |
Liver metastasis | |
 Yes | 10 (11.8%) |
 No | 75 (88.2%) |
Brain metastasis | |
 Yes | 13 (15.3%) |
 No | 72 (84.7%) |
Bone metastasis | |
 Yes | 47 (55.3%) |
 No | 38 (44.7%) |
ICIs treatment Protocols | |
 ICIs + Chemo | 43 (50.6%) |
 Nivolumab combinations | 1 (1.2%) |
 Pembrolizumab combinations | 11 (12.9%) |
 Camrelizumab combinations | 6 (7.1%) |
 Tislelizumab combinations | 4 (4.7%) |
 Toripalimab combinations | 14 (16.5%) |
 Sintilimab combinations | 7 (8.2%) |
 ICIs + Anti-VEGFR | 23 (27.1%) |
 Pembrolizumab plus bevacizumab | 6 (7.1%) |
 Camrelizumab plus anlotinib | 3 (3.5%) |
 Atezolizumab plus bevacizumab | 3 (3.5%) |
 Toripalimab plus bevacizumab | 1 (1.2%) |
 Toripalimab plus anlotinib | 1 (1.2%) |
 Sintilimab plus bevacizumab | 1 (1.2%) |
 Sintilimab plus anlotinib | 8 (9.4%) |
 ICIs + Chemo + Anti-VEGFR | 19 (22.3%) |
 Pembrolizumab combinations | 3 (3.5%) |
 Camrelizumab combinations | 2 (2.4%) |
 Atezolizumab combinations | 7 (8.1%) |
 Tislelizumab combinations | 3 (3.5%) |
 Toripalimab combinations | 2 (2.4%) |
 Sintilimab combinations | 2 (2.4%) |
EGFR mutation status | |
 Exon 19 deletion | 45 (53.0%) |
 L858R mutation | 33 (38.8%) |
 G719X mutation | 2 (2.4%) |
 L861Q mutation | 3 (3.4%) |
 Exon 20 insertion | 2 (2.4%) |
T790M mutation status | |
 Positive | 26 (30.6%) |
 Negative | 24 (28.2%) |
 Unknow | 35 (41.2%) |
 TP53 status | |
 Positive | 20 (23.5%) |
 TP53-19 del co-mutation | 8 (9.4%) |
 TP53-L858R co-mutation | 11 (12.9%) |
 TP53- G719X co-mutation | 1 (1.2%) |
 Negative | 21 (24.7%) |
 Unknow | 44 (51.8%) |
TKI-PFS | |
  < 10 | 49 (57.6%) |
  ≥ 10 | 36 (42.4%) |
Prior EGFR-TKI | |
 1st EGFR-TKI | |
  Gefitinib | 15 (17.6%) |
  Erlotinib | 2 (2.4%) |
  Icotinib | 27 (31.8%) |
2nd EGFR-TKI | |
 Afatinib | 4 (4.7%) |
3rd EGFR-TKI | |
 Osimertinib | 37 (43.5%) |